ETX101, a targeted gene regulation therapy developed by Encoded Therapeutics, showed durable seizure reduction and early neurodevelopmental gains in children with SCN1A-positive Dravet syndrome during the Phase I/II POLARIS trial. Data were presented at the American Society of Gene and Cell Therapy (ASGCT) Presidential Symposium, underscoring the therapy's potential for this severe epileptic encephalopathy.
The POLARIS trial enrolled pediatric patients with confirmed SCN1A mutations, a key driver of Dravet syndrome. Results demonstrated consistent seizure reduction alongside developmental progress, including improvements in motor and cognitive skills. No new safety signals emerged, supporting the therapy's tolerability. Dravet syndrome, which typically emerges in infancy, is marked by frequent, drug-resistant seizures and developmental delays.
Encoded Therapeutics designed ETX101 to upregulate expression of the healthy SCN1A allele, a novel regulatory approach distinct from traditional gene replacement. The therapy is administered intrathecally and has received Rare Pediatric Disease and Orphan Drug designations from the FDA, positioning it for accelerated review. A pivotal trial is expected to follow the positive Phase I/II data.
Encoded Therapeutics, a privately held firm, has not disclosed stock impact, but the data represent a significant de-risking event. The Dravet syndrome market is estimated to exceed $1.5 billion globally, with approved therapies including fenfluramine and cannabidiol-based drugs. ETX101's regulatory advantage could capture substantial market share if approved.
Experts caution that these are early-stage results from a small cohort, and long-term durability data are needed. The therapy's intrathecal delivery also carries procedural risks not associated with oral medications. Nonetheless, the molecular approach—modulating endogenous gene expression rather than replacing it—offers a paradigm shift for genetic epilepsies.